Summary
The 1Q of FY2027/3 marks the first quarter in which the results of the large-scale structural reforms implemented in the prior fiscal year will be reflected. With the exit from unprofitable businesses (RiLi casting, apparel, lifestyle support, etc.) now complete, and resources concentrated on brand production and niche-top strategy under the new operating structure, the key focus is the extent to which three growth pillars—full-year contribution from Kanarabo (Fujiko/b idol), bialne growth at HaD, and MiiS's expansion into oral beauty—will drive revenue and earnings. The company listed on the Growth Market in June 2024 and operates a distinctive model combining inorganic growth through M&A with brand development centered on social media marketing. With goodwill of JPY 2.311B and an equity ratio of just 19.2%, investors need to carefully assess 1Q progress toward the full-year operating income target of JPY 50M (return to profitability).
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Revenue GrowthConsolidated revenue run-rate with Kanarabo's first full-quarter contribution | Whether 1Q revenue exceeds JPY 1.5B (our estimate: ~23% of full-year target) is a prerequisite for breakeven, against the full-year plan of JPY 6.602B |
Profitability ImprovementYoY trends in gross profit margin and SG&A ratio | In the prior year, gross profit margin was 53.6% vs. SG&A ratio of 63.3%, resulting in an operating loss. We estimate a 5pt+ reduction in SG&A ratio is needed to reflect the impact of exiting unprofitable businesses |
Adjusted EBITDAEarning power before goodwill amortization and acquisition-related costs | 1Q progress toward the full-year target of JPY 324M (vs. JPY -118M in prior year). We estimate JPY 80M+ per quarter as the benchmark |
Goodwill / Impairment RiskRecoverability of JPY 2.31B goodwill balance | Goodwill accounts for 40.9% of total assets. Need to verify whether business plans remain on track at Kanarabo (JPY 694M), NADESIKO (JPY 609M), Tokakai/MOM (JPY 481M), and others |
Financial SoundnessTrends in equity ratio and interest-bearing debt | Equity ratio has declined to 19.2% (from 32.7% in the prior year). Refinancing status of JPY 820M in short-term borrowings + JPY 944M in current portion of long-term debt is critical for liquidity |
New BusinessInitial revenue contribution from Oripa business and MiiS LIFT BRUSH | The trading card investment / online gacha business has unclear synergies with existing brand production operations. MiiS's beauty appliance rollout could enhance LTV as a high-ASP product line |
Capital EfficiencyRecovery trend in ROE and ROIC | ROE was -32.8% in the prior year. Even with the full-year adjusted net income target of JPY 128M, meaningful ROE improvement is limited; need to assess the specificity of medium-term capital efficiency enhancement measures |
Key Issues from Previous Results (FY2026/3 Full-Year Results)
The prior fiscal year delivered M&A-driven revenue growth (+38.3%), but was weighed down by Kanarabo's sales shortfall vs. plan, declining orders in other new business areas, and JPY 304M in goodwill impairment at the RiLi business, resulting in a deterioration to an operating loss of JPY -399M. That said, adjusted net income of JPY 310M (+95.0%) was secured, and the year can be characterized as one in which the company executed structural reforms and completed its pivot to a niche-top strategy. In FY2027/3, the reorganized group structure enters its first full quarter, and the focus shifts from growth in "quantity" to growth in "quality."
1. Full-Year Contribution from Kanarabo (Fujiko/b idol) and Distribution Expansion
- Prior Year: 5-month consolidated contribution period (November 2025–March 2026). Estimated revenue impact assuming start-of-year consolidation was +JPY 1.382B
- This Quarter's Focus: Whether the introduction into approximately 3,000 drugstore locations (announced July 2026) can offset revenue declines in the variety store channel through channel mix diversification
- Key Metrics: Kanarabo standalone quarterly revenue (our estimate: annual revenue of JPY 2.0B+ is implied in the full-year plan), gross margin trends
2. Restructuring and Earnings Contribution From Other New Business Areas
- Prior Year: Order declines driven by client ad budget reductions and accelerating in-housing. Revenue from the divested business prior to the Rice Curry LS transfer was JPY 448M (operating income JPY 188M)
- This Quarter's Focus: Recovery in RCP's order pipeline following the food & beverage specialization. Revenue erosion from the divestiture and resulting margin profile changes
- Key Metrics: Quarterly revenue in the other new business segment, OPM (compared with prior-year levels for RCP as a whole)
3. Appropriateness of Goodwill Balance and Impairment Risk Management
- Prior Year: Goodwill balance of JPY 2.31B (40.9% of total assets). JPY 304M goodwill impairment booked at WinC. Goodwill amortization of JPY 161M
- This Quarter's Focus: Business plan progress at Kanarabo (JPY 694M / 10-year straight-line), NADESIKO (JPY 609M / 10 years), and Tokakai/MOM (JPY 481M / 20 years)
- Key Metrics: Quarterly goodwill amortization (our estimate: ~JPY 230M annually), any signs of additional impairment
4. Financial Stability and Cash Flow Improvement
- Prior Year: Operating CF JPY -676M, cash balance JPY 689M. Short-term borrowings JPY 820M, current portion of long-term debt JPY 944M
- This Quarter's Focus: Outlook for operating CF turning positive. Normalization of inventory at JPY 954M (up +234% from JPY 285M in the prior year)
- Key Metrics: Quarterly operating CF, cash balance trajectory, debt service coverage ratio (our estimate: annual principal and interest payments exceed JPY 600M)
5. Monetization Progress in Oral Beauty and Clinic Business
- Prior Year: Tokakai/MOM consolidated (September 2025). Estimated operating loss of JPY -146M on a start-of-year pro forma basis. Harukikai was treated as acquired at fiscal year-end (balance sheet consolidation only)
- This Quarter's Focus: Revenue contribution from MiiS LIFT BRUSH (JPY 14.5M on Makuake → general release in August), timeline to monthly breakeven for the clinic business
- Key Metrics: Oral beauty-related revenue, quarterly operating income/loss in the clinic business
Timely Disclosure & Industry Trends
- 2026/07/22MiiS LIFT BRUSH General Release — Following JPY 14.5M in crowdfunding on Makuake (4,831% funded), sales commenced on the official website, Amazon, Rakuten, and nationwide LOFT stores. Focus is on 1Q revenue contribution from the expansion of the high-ASP oral beauty product line. MiiS LIFT BRUSH General Release
- 2026/07/10Fujiko "Keana Odamari! Cream" Launched in ~3,000 Major Drugstore Locations — Cumulative sales surpassed 110K units within 1.5 months of launch, exceeding 180% of the wholesale division's plan. This represents a critical assumption underpinning the full-year plan as the company diversifies away from variety store dependence. Fujiko Major Drugstore Launch
- 2026/06/23Fujiko/b idol Win Multiple 1H 2026 Best Cosme Awards — Best cosme awards from beauty magazines validate brand awareness and equity. Fujiko's new products are tracking at approximately 3x the initial sales plan. Fujiko/b idol Best Cosme Awards
- 2026/06/17Entry Into Trading Card Investment and Oripa Business — Announced entry into the online gacha service "Oripa Shop" as a "growth-redistributive treasury strategy." Synergies with existing brand production operations are limited, and monitoring is warranted from the perspective of business focus and selection. Trading Card Investment / Oripa Business Entry
Previous Quarter Results (FY2026/3 Full-Year Results)
MUSCAT GROUP operates as a "brand production company," running proprietary brands (brand production segment) and providing social media marketing support for corporations (other new business segment). Following its listing on the Growth Market in June 2024, the company aggressively pursued M&A under a niche-top strategy, consolidating Kanarabo (Fujiko/b idol), HaD (bialne), Tokakai/MOM (oral beauty clinics), and others. In the prior fiscal year, M&A-driven consolidation scope expansion fueled +38.3% revenue growth, but the company swung to an operating loss due to Kanarabo's sales shortfall, declining orders in the other new business segment, and impairment charges at the RiLi business. The company executed structural reforms, completing its exit from unprofitable businesses and transition to a holding company structure.
| Item | Amount | YoY | vs. Guidance | Remarks |
|---|---|---|---|---|
| Revenue | JPY 4.129B | +38.3% | - | Primarily driven by consolidation scope expansion via M&A |
| Operating Income | JPY -399M | - | - | Swung to a loss from JPY 88M in the prior year. SG&A ratio rose to 63.3% |
| Recurring Profit | JPY -451M | - | - | Pressured by interest expense of JPY 56M (vs. JPY 21M in the prior year) |
| Net Income | JPY -368M | - | - | JPY 304M goodwill impairment, JPY 205M DTA write-down. Partially offset by JPY 710M gain on sale of affiliate shares |
| EPS | JPY -121.46 | - | - | Deteriorated from JPY 38.68 in the prior year |
Guidance Achievement Rate vs. Full-Year Plan: Not calculable as the company did not disclose full-year guidance for FY2026/3. Note that FY2027/3 full-year guidance calls for revenue of JPY 6.60B and operating income of JPY 50M.
Company Information
- Company Name: MUSCAT GROUP Inc.
- Ticker: 195A
- Exchange: Tokyo Stock Exchange Growth Market
- Fiscal Year-End: March
- Core Business: Brand production business (proprietary brand operations, brand portfolio expansion through M&A, social media marketing support for corporate clients)
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

